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ABPM ambulatory blood pressure monitoring 
AC adenile cyclase 
ACE angiotensin converting enzyme 
ADP adenosine diphosphate 
ANS 8-aniline-l-naphthalene sulphate 
ATP adenosine triphosphate 
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MCNS minimal change nephrotic syndrome 
MGN membranous nephropathy 
MPGN membranoproliferative glomerulonephritis 
NO nitric oxide 
NOx nitric oxide end products (N02/N03) 
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PAF platelet activating factor 
PD peritoneal dialysis 
PDGF platelet-derived growth factor 
PGEi prostaglandin Ei 
PGI 2 prostacyclin 
PPP platelet-poor plasma 
PRP platelet-rich plasma 
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RAS renin-angiotensin system 
RBC red blood cell 
rHu-EPO recombinant human erythropoietin 
SLE systemic lupus erythemathosus 
TxA2 thromboxane A2 
T X B 2 thromboxane B2 
VLDL very low density lipoprotein 
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SUMMARY 
This thesis focuses on platelet functional disturbances in three groups of paediatric patients: 
children with nephrotic syndrome, children and adolescents with end stage-renal failure in a 
chronic haemodialysis programme and hypertensive children and adolescents. 
Our study did not reveal any significant difference in the results of platelet aggregation, ATP 
release, TxB2 release, or platelet cAMP concentration between steroid-treated and non-treated 
patients. The plasma cholesterol and triglyceride levels were significantly higher in relapse than 
in remission; nevertheless, no differences in platelet function were seen between these groups. In 
conclusion oral prednisone therapy on alternate days and the high cholesterol and triglyceride 
level in the plasma cannot be responsible for the hyperaggregation of platelets in nephrotic 
children. The increased platelet aggregability and TxB2 release suggesting that abnormalities 
may be involved in the pathogenesis of both MCNS and FSGS. The platelets TxB2 is 
significantly higher in FSGS than in MCNS, which may be have an impact in the progression of 
glomerular damage by an increased vasoconstriction and intraglomerular pressure. Our results 
demonstrate that platelets from dialysed or non-dialysed ESRF patients display a significantly 
higher cAMP, a lower TxB2 and a lower aggregability, than those of the controls. Our 
observations seem to confirm that there is no correlation between the serum PTH level and the 
degree of disturbances of the biochemistry and aggregation of platelets of ESRF patients. The 
platelet cAMP level decreased more markedly during bicarbonate HD, than during acetate HD, 
and greater increases in platelet aggregation and TxB2 formation were observed following 
bicarbonate HD. As the normalisation of the bleeding time following 1 year of rHu-EPO therapy 
was not associated with the normalisation of the platelet aggregability and biochemistry, we can 
not exclude the role of the increased Hct in the shortening of the bleeding time. However, the 
increased RBC count did not improve the platelet aggregation. Although rHu-EPO itself did not 
improve the platelet aggregation directly during 1 year of rHu-EPO therapy, a number of platelet 
functional changes were observed, including increased aggregability, and ATP and TxB2, release 
and a decrease in cAMP concentration. These contribute to the improvement of the bleeding 
time. Therefore we consider that rHu-EPO therapy can improve the platelet function through 
biochemical changes and has a combined effect on the haemostasis of ESRF patients. Increased 
platelet aggregation and TxB2 are characteristic feature of juvenile essential hypertension and 
ESRF associated hypertension, contributing the blood pressure elevation, while hyperlipidaemia 
is more common in ESRF, regardless blood pressure and does not have a role in the pathogenesis 
of JEHT at an early stage. In addition JEHT patients exhibits a compensatory increases in plasma 
NO level. 
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1. I N T R O D U C T I O N 
1.1. Platelets 
The main role in the maintenance of haemostasis is played by the platelets. These fulfil a 
number key functions, these being highly dependent not only on their number but, also on their 
integral physiology. Resting, unstimulated platelets circulate without adhesing to the vessel wall 
and without aggregating, but they respond rapidly to exposure to subendothelial matrix proteins, 
such as collagen, von Willebrand factor (vWF), fibronectin, or laminin by disruption of the 
endothelial layer. Thus, the endothelium serves as physical barrier to prevent platelet activation 
by contact with subendothelial matrix proteins and additionally exerts antithrombotic effects by 
the production of prostacyclin (PGI2) and nitric oxide (NO) productions. (5,15>97) 
The platelet activation processes are initiated by the platelets coming into contact with 
subendothelial matrix proteins and circulating soluble pro-aggregatory agents (e.g.endothelin-1 
(ET-1) and thromboxane A2 (TxA2)). These processes result in adhesiveness and the subsequent 
activation and recruitment of more platelets (platelet-platelet interaction), leading to an occlusive 
haemostatic plug. This is the process of primary haemostasis ( 5 ) . (Fig. 1) 
Colagen 
Fig 1. Platelet-vessel wall and platelet-platelet interaction 
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The activation of platelets is associated with marked morphological changes: the 
discoid form of resting platelets is changed to a more spherical appearance of stimulated platelets 
(shape change), which is accompanied by a complex cytoskeletal reorganisation |69>. The 
transformed platelets have an increased membrane reservoir and an increased potential to attach 
irreversibly to the altered vascular surface by a process called adhesion. Adhesion is mediated by 
the platelet membrane glycoproteins GPIa-Ila, GP-Ib-V-IX and GPIc-IIa, which serve as 
receptors for collagen, vWF and fibronectin, respectively <37). 
PGI, 
TxAj 
Thrombin 
Serotonin 
ADP 
Collagen 
Thrombin 
Epine phrin 
ADP ADP Ca" 
\ / \ 
AC t Rho PLC t A C i 
CAMP T ATP 
1 
IP, + DAG PIP, CAMP i ATP 
Shape change 
Inhibition of activation 
Ca" 
V 
( O U * Aggregation < ¿ ¡ N j 
V _ 7 Release 
Release of inhibition 
to 
Fig. 2. The platelet activation and inhibition of activation 
(IP3: inositol 1,4,5-triphosphate, DAG: diacylglycerol, PIP2 :phosphatidylinositol-4,5 biphosphate) 
Adhesion is followed by subsequent platelet-platelet interactions called aggregation. 
This process is mainly mediated by the interaction between the fibrinogen and the platelet-
specific GPIIb-IIIa complex. Additionally, the platelets release their secretory granules (a-
granules and dense bodies). The platelet-derived growth factor (PDGF), P-thromboglobulin, 
platelet factor 4 and other coagulation factors are localised in a-granules. The principal 
constituents of dense granules are non-metabolic pools of adenine nucleotides (adenosine 
triphosphate and diphosphate: ATP and ADP), PPi, Ca2 and Mg2 ' , P-selectin and serotonin (5-
hydroxytriptamine). The adenine nucleotides are synthesised and segregated by megakariocytes. 
In addition the dense bodies contain guanosine triphosphate and diphosphate (GTP and GDP), 
which are the targets of the anti-platelet effects of endothelial NO, elevating the cyclic guanosine 
monophosphate (cGMP) level in the platelets. Both ADP and ATP produce adenosine 
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monophosphate (AMP); this is dephosphorylated to adenosine, which ultimately forms cyclic 
AMP (cAMP), which inhibits the platelet stimulatory response (8'69). (Fig.2) 
The agonists elevate the cytosolic Ca2+ concentration in human platelets via a receptor-
operated mechanism, involving both Ca2+ release from intracellular stores and subsequent Ca2+ 
entry, which can be inhibited by platelet inhibitors such as prostaglandin El (PGEi) and NO 
donors which, elevate the cAMP and cGMP levels, respectively. The secreted ADP and TxA2 
activate more platelets; this process is called the release reaction (5'8). (Fig. 1) 
Furthermore the platelets are closely linked to plasmatic coagulation system and 
contribute to thrombin and subsequent fibrin generation. Coagulation factors such as factor V, 
factor XI and others are stored in the platelet a-granules, secreted upon platelet stimulation and 
expressed at the cellular membrane, which serves as a surface for various enzymatic reactions of 
the coagulation cascade (5'37'69). 
Table 1. Testing of platelet function 
Bleeding time: 
Screening test for quantitative platelet disorders 
(Platelet activation, adhesion and aggregation) 
Aggregation test: 
Measurement of the formation platelet clumps in platelet-rich plasma (PRP) 
following stimulation with ADP, collagen, epinephrine, arachidonic acid, 
ristocetin, thrombin and platelet activating factor (PAF) 
Release reaction analysis: 
Platelet-specific a-granules proteins: 
Platelet factor 4, p-thromboglobulin, PDGF 
and soluble P-selectin (CD62P) 
Platelet dense granules: 
ATP, ADP, serotonine and CD63 
CD63 and CD62P analysed by flow cytometry 
Platelet adhesion test: 
Monoclonal antibodies against GPIb-V-IX and (31-integrins 
Platelet procoagulant activities: 
Platelet factor 3 
Platelet prothrombinase activity 
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Platelet function analysis in children and adolescents may involve the studies bleeding 
time, platelet aggregation, secretion (release reactions) and measurements of platelet 
procoagulant activity. Analysis of platelet membrane glycoproteins (GPs) on resting and 
stimulated platelets by flow cytometry has become available (Table 1.). 
This thesis will focus on platelet functional disturbances in three groups of paediatric patients: 
- Children with nephrotic syndrome (NS) 
- Children and adolescents with end stage-renal failure in a chronic haemodialysis 
programme 
- Hypertensive children and adolescents 
1.2. Nephrotic syndrome and platelet function 
The term nephrotic syndrome is applicable to a condition characterised by heavy 
proteinuria, hypoproteinaemia, hyperlipidaemia and oedema. (Table 2.) 
Table 2. Definitions of nephrotic syndrome(4) 
Nephrotic syndrome: Oedema, plasma albumin < 25 g/1, proteinuria > 40mg/m2/hr 
or protein/creatinine ratio > 200mg/mmol 
Remission: Urinary protein excretion < 40mg/m2/hr or Albustix = 0/trace for 
3 consecutive days 
Relapse: Urinary protein excretion > 40mg/m2/hr or Albustix ++ or more for 3 consecutive days having previously 
been in remission 
It is a disorder of glomerular permselectivity and charge selectivity that may be primary 
or secondary to an overt systemic disease (e.g. SLE). In children, the nephrotic syndrome is an 
uncommon disorder (cumulative prevalence 15.7 per 100 000 children). The International Study 
of Kidney Disease in Children (ISKDC) reported that 77% of nephrotic children had minimal 
change nephrotic syndrome (MCNS); focal segmental glomerulosclerosis (FSGS) was present in 
10%, membranoproliferative glomerulonephritis (MPGN) in 5%, diffuse mesangial proliferation 
in 3%, crescentic glomerulonephritis in 3% and membranous nephropathy (MGN) in 2%. It is 
unclear whether MCNS and FSGS should be considered to be separate entities or different ends 
of a single spectrum of disease. Current opinion tends to group the two under the rubric of 
idiopathic nephrotic syndrome (INS), as there are examples of MCNS evolving into FSGS 
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However, in their typical expression, the two disorders differ not only in glomerular histology 
and response to corticosteroid therapy, but most importantly in the tendency for FSGS to 
progress to end stage renal failure (ESRF), which hardly ever happen in MCNS(4). 
In current clinical practice, most centres accept a high dose prednisolone (60 mg/m2/day) 
for the induction of remission. After remission has been achieved, the dose of prednisolone is 
reduced to 40 mg/m2/ alternate day for the next 4 weeks(4). 
The platelet vessel-wall interaction has an important role in the pathogenesis of 
glomerular diseases. We have presented data, that there is a reduced level of plasma factors 
influencing PGI2-like activities and platelet aggregation in patients with IgA nephropathy and 
Hennoch-Schonlein purpura (101). Various abnormalities in both coagulation and the fibrinolytic 
system have been observed in many nephrotic syndrome patients (1,u,65). The plasma from 
nephrotic patients is hypercoagulable with high levels of fibrinogen, factor VIH:RAg and a2-
macroglobulin and with reductions in both functional and immunologic antithrombin III. 
Antithrombin III concentration is reduced due to the urinary loss and the plasma is resistant to 
anticoagulation with heparin (95) . Because of the hypovolemia, the microcirculation is sluggish, 
while the blood is viscous due to the haemoconcentration. Ueda et al.(102) postulate that steroid 
treatment acts as a thrombogenetic factor by accelerating thrombocytosis and hyperlipidaemia 
and by reducing plasma fibrinolysis in children with MCNS. The lipoproteins have been shown 
experimentally to be harmful for damaged and sclerotic glomeruli. The clinical implication of 
these changes is not clear, although they result in a hypercoagulable state with increased 
thromboembolic problems and in the progression of glomerulosclerosis (9'50'51). Bang et al. (3) 
found that the degree of platelet dysfunction was correlated with the amount of proteinuria and 
the level of hypoalbuminaemia. The platelet counts within the glomeruli rise in several renal 
diseases, but not in MCNS. The spontaneous aggregation of the platelets and aggregation in 
response to collagen and ADP are enhanced (1'3). The platelets adhere to the damaged endothelial 
surface and release their granular contents consisting of PDGF, serotonin and thromboxane A2 
(TxA2). In glomerular disease, the increased platelet aggregation is frequently associated with an 
elevated production of PAF, and therapy with specific PAF antagonists has prevented or reduced 
proteinuria(78). In MGN, a significant positive correlation has been detected between the urinary 
excretion of PAF and proteinuria (74). The platelet deposition in glomerulosclerosis and the 
release of PDGF, PAF and TxA2 could cause further increases in platelet aggregation and local 
vasoconstriction, and result in the progression of glomerular damage. 
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1.3. Platelet function in ESRF patients 
Patients with uncontrolled renal failure exhibit a haemorrhagic tendency (57). A number of 
early studies have reported a prolonged bleeding time, a decreased platelet count (27'58), and a 
reduced platelet factor 3 availability (86,109>. In vitro platelet aggregation studies have led to 
conflicting results. 
Table 3. Causes of the haemostatic defect in ESRF(76) 
Platelet abnormalities 
Subnormal dense granule content 
Reductions in intracellular ADP and serotonin 
Impaired release of platelet a-granule protein and P-thromboglobulin 
Enhanced intracellular cAMP 
Abnormal mobilisation of platelet Ca2+ 
Abnormal platelet arachidonic acid metabolism 
Abnormal ex vivo platelet aggregation in response to different stimuli 
Defective cyclooxygenase activity 
Abnormal GP Da-Ilia binding 
Uremic toxins 
Abnormal platelet-vessel wall interaction 
Abnormal platelet adhesion 
Increased formation of vascular PGI2 
Altered vWF 
Anaemia 
Altered blood rheology 
Erythropoietin deficiency 
Abnormal NO production 
Drug treatment (non-steroid antiinflammatory drug, antihypertensive, etc.) 
A reduced aggregation, in response to ADP, epinephrine, collagen and thrombin, has 
been reported by some investigators (46'62'84), but others have found an enhanced aggregability 
(27,ii3) § e v e r a j biochemical abnormalities have been observed in platelets from uraemic subjects. 
T X B 2 production in response to exogenous arachidonic acid was normal, whereas it was 
decreased by 40-50% in response to collagen and thrombin (19), which reflects a decreased 
release of arachidonic acid from platelet phospholipids. On the other hand, there are reductions 
in ATP secretion in response to thrombin, collagen and arachidonic acid, associated with a 
reduced ADP content of the dense granules, suggesting a storage pool defect(19). An elevation in 
the cAMP level (108) in ESRF patients could contribute to a defective aggregation response by 
reducing the availability of intracytoplasmatic Ca2+. There are conflicting results on the role of 
parathyroid hormone (PTH) in uremic thrombocytopathy (20'63). Noris and Remuzzi(76) recently 
published data indicating that monomethyl-L-arginin (L-NMMA), and NO inhibitor, normalised 
the platelet dysfunction and bleeding time in experimental uraemia, suggesting the crucial role of 
NO. The pathogenesis of uremic bleeding is considered to be multifactorial (Table 3.), but the 
platelet-platelet and platelet-vessel wall interaction appear to be of crucial importance (76). 
Modern dialysis techniques and the use of recombinant human erythropoietin (rHu-EPO) reduce 
the frequency of bleeding in ESRF. 
Erythropoietin is the primary regulator of red blood cell (RBC) production and furnishes 
a major advantage in the treatment of anaemia in the ESRF (30,45'110). rHu-EPO enhances the 
growth-promoting action of thrombopoietin on the megakaryocytes and therefore elevates the 
platelet production. The side effects of rHu-EPO are considered to be minimal; hypertension and 
thrombotic events have been reported in haemodialysis (HD) patients during clinical trials 
(12,33,95,106,107) jt j^g a i s o b e e n stated to shorten the skin capillary bleeding time, indicating a 
correction of the uraemic bleeding tendency. The decrease in the bleeding time after treatment 
with rHu-EPO could be due to elevation of the haematocrit (Hct), with an increased blood 
viscosity, or to changes in the platelet function or both. A number of studies have examined, how 
rHu-EPO could improve the primary haemostasis. Gorge et al. (39) found that the shortening of 
the prolonged bleeding time following rHu-EPO treatment was due to an increase in the 
circulating RBCs. Fabris et al. (33) observed that correction of the anaemia with rHu-EPO was 
followed by an improved platelet aggregation and the serum TxB2 levels rose to the normal 
range. They concluded that treatment with rHu-EPO improved the haemostasis not only by 
correcting the anaemia, but also by increasing the platelet count and function. In contrast with 
the platelets, which are clearly affected, rHu-EPO does not appear to have a significant effect on 
the blood coagulation and fibrinolytic factors. 
In addition to these observations, increasing evidence has accumulated on the role of 
surface negative charge on the platelets, preventing their aggregation and adhesion to the 
endothelial cell. In most blood cells the resultant membrane surface charge is negative, but may 
be altered by factors such as pH, proteins and phospholipids (32'52'67). 
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1.3 Hypertension in children and adolescents 
Hypertension is an important cause of vascular morbidity and mortality in adults, and in 
the majority it is essential and multifactorial in origin. In childhood it is less common and if 
severe, is usually secondary with 90-95% of the cases due to renal disease. In the patients with 
ESRF the high blood pressure (BP) remains a major problem and it is probably responsible for a 
sizeable portion of the morbidity imposed by cardiovascular disease in dialysis patients (I6). The 
endothelium emerged as an important participant in a number of human diseases, because it 
controls the vasomotor tone by releasing number of substances. Some of these have 
vasoconstrictive effect (ET-1, TxA2), others cause vasodilatation (NO, PGI2, bradykinin)(72). 
NO, which was identified in 1980 as the endothelial dependent relaxing factor (EDRF), is an 
important mediator of the vascular tone. NO mediates vasodilatation, inhibits the platelet 
aggregation and expression of adhesion molecules for monocytes and neutrophils, and impairs 
the growth of vascular smooth muscle cells (71). Hypertension is one of a number of 
cardiovascular risk factors (83) (including diabetes mellitus and hypercholesterolemia) for the 
development of atherosclerosis, in which endothelial, NO and platelet dysfunctions are known to 
play an important part (20'66). The role of NO in childhood hypertension is less well defined. 
Goonasekera et al. (38) found evidence of an increased NO activity in the plasma of hypertensive 
children. An increased oxidative stress, decreasing the bioavailability of NO, is mainly 
responsible for a blunted endothelium-dependent vasoreactivity (105). Whereas ET-1 has a 
relatively small influence on the basal regulation of the blood pressure, NO appears to play a 
central role under normal conditions (66). On the other hand, in pathological states, a balance 
between NO and local ET-1 production may be central to changes in blood vessel reactivity, 
smooth muscle proliferation and blood coagulability. The opposing actions of NO and 
angiotensin II (Ang II) in vascular contraction, vascular smooth muscle cell proliferation and 
apoptosis are well documented (108). Various experimental approaches have demonstrated that 
NO negatively modulates the renin-angiotensin system (RAS) by inhibiting the angiotensin 
converting enzyme (ACE) activity and down-regulating the AT-1 receptors. NO also inhibits the 
proliferation and migration of vascular smooth muscle cells induced by Ang II. NO has emerged 
as a factor regulating the RAS at different levels, while Ang II seems to have a regulatory 
influence on NO generation (23'72). 
Under physiological conditions, there is equilibrium between pro-aggregating and anti-
aggregating factors. The adult patients with hypertension display a state of platelet 
hyperaggregability, even if there is no other risk factor for cardiovascular disease. The platelet 
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aggregation, the P-selectin (CD62) expression on platelet surface, the serum levels of IL-ip and 
IL-6, and plasma levels of soluble P-selectin and ET-1 are reduced with the normalisation of 
blood pressure (91'92). Dockrell et al.(22) demonstrated that enhanced platelet sensitivity to ET-1 in 
young men with high blood pressure appears to be a feature of familial predisposition to 
hypertension. 
Diabetes mellitus, cigarette smoking, hypercholesterolaemia and an increased body mass 
index (BMI) are well known risk factors in adults. Experimental and clinical data suggest an 
important interaction between hyperlipidaemia and hypertension. Not only do they frequently 
coexist, but also hypertension dramatically exaggerates hyperlipidaemic injury and substances, 
which maintain the vascular tone (49'83). The occurrence and role of this metabolic state have not 
been investigated in children. 
2. AIMS OF THE STUDY 
The following questions were considered during investigation of platelet function in 
children and adolescents with kidney diseases and hypertension. 
2.1. Platelet aggregation studies in nephrotic syndrome 
2.1.1. How is the platelet Junction changed in children with nephrotic syndrome? 
2.1.2. Do steroid treatment and hyperlipidaemia influence the platelet function in nephrotic 
syndrome? 
2.1.3. Are there differences in platelet function in the patients with MCNS as compared to 
FSGS? 
2.2. Effect of haemodialysis and rHu-EPO on platelet aggregation 
2.2.1. How is the platelet function changed in children with ESRF? 
2.2.2. Can bicarbonate and acetate HD improve the platelet function in ESRF? 
2.2.3. How does the platelet surface charge change during HD in ESRF? 
2.2.4. Can the one-year rHu-EPO treatment improve the platelet function in ESRF? 
2.3 The role ofplatelet function, thromboxane and nitric oxide in hypertension of children 
and adolescents 
2.3.1. Does high blood pressure influences the plateletfunction in children and adolescents? 
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2.3.2. Is there any difference in platelet junction in essential and secondary, ESRF-associated 
hypertension in childhood? 
2.3.3. Is there any role of hyperlipidaemia in the pathogenesis of essential hypertension in 
childhood? 
2.3.4. Can the NO regulate the platelet function in hypertension? 
3. PATIENTS 
None of the patients received non-steroid anti-inflammatory drugs, albumin or blood 
transfusion in the 2-week period prior to the studies. Neither the patients, nor controls received 
any medication known to affect the platelet function. 
The following groups of patients were investigated: 
3.1. Platelet aggregation studies in nephrotic syndrome 
3.1.1 Platelet aggregation in nephrotic syndrome 
57 patients with nephrotic syndrome (28 boys and 29 girls, aged 4-17 years) and 18 age-
and sex-matched controls were studied. 34 patients were in relapse (urinary protein >3 g/24 h, 
plasma albumin 20±3 g/1 (±SEM) and 23 were in early (< 6 month) remission (urinary protein =0 
g/24h, plasma albumin 26±2g/l). Histological examination of kidney biopsy specimens indicated 
that 25 patients had MCNS, 9 had FSGS, 6 had MPGN, 6 had IgA nephropathy (IgAN), 7 had 
SLE and 4 had MGN. Only one patient had unilateral renal vein thrombosis 8 months before the 
study and received 60mg/m2/day prednisolone treatment. 
None of the other patients had renal or extrarenal thrombotic complication. All the 
patients in relapse were treated with 0.5mg/kg/alternate day prednisolone as part of the 
immunosuppressive therapy with chlorambucil or azathioprine, or 1.0 mg/kg prednisolone 
monotherapy every other day in MCNS. 12 patients in remission were still on tapering dose of 
prednisolone, and 11 did not received treatment. 
3.1.2. Comparison ofplatelet function in MCNS and FSGS 
16 patients with FSGS (8 adults and 8 paediatric cases) 27 children with MCNS (12 in 
relapse and 15 remission) and 12 adult (aged 31+5.0 years) and 15 paediatric controls were 
investigated. None of the patients had renal or extrarenal thrombosis. The diagnostic criteria for 
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relapse are given in section 3.1.1. All MCNS patients in relapse were treated with 60mg/m2/day 
prednisolone and those with FSGS received 2.0mg/kg/day cyclophosphamide and 
35mg/m2/alternate day prednisolone. 
Table 4. Histological distribution of patients with NS 
NS in remission NS in relapse 
MCNS 
Prednisolone + 7 11 
Prednisolone - 7 -
FSGS 
Prednisolone + - 11 
MPGN 
Prednisolone + - 5 
IgAN 
Prednisolone + 1 2 
Prednisolone - 3 -
SLE 
Prednisolone + 4 3 
MGN 
Prednisolone + - 3 
Prednisolone - 1 -
23 33 
3.2. Platelet aggregation studies in ESRF 
3.2.1. Effects of bicarbonate and acetate haemodialysis on platelet aggregation 
6 patients with ESRF' (3 boys and 3 girls, aged 7-16 years) who had been on HD 
treatment for 27.4 months (10-68 months) (group 1), 8 patients with ESRF (5 boys and 3 girls, 
aged 4-15 years) on conservative treatment (group 2) and 10 age- and sex-matched controls 
were investigated. The primary diagnosies in group 1 and group 2 were 5 cases of chronic 
glomerulonephritis, 3 of hydronephrosis, 4 of renal agenesia with contralateral hypoplasia, 1 of 
nephrosclerosis and 1 of polycystic kidney disease. The patients from group 1. and 2. had a 
history of bleeding tendency (easy bruising, and nose and gum bleeding). The patients in group 1 
had a pre-dialysis Ivy bleeding time of 9.5+0.7 min., while that in the controls was 4.7+0.9 min. 
The patients in group 1. were each treated with 5 acetate and 5 bicarbonate HD. (cuprophan 
dialyser, blood flow 200 ml/min, duration 210min.) Heparin was administered in an initial dose 
of 2000 IU and which was followed by a 1200 IU/hr constant infusion. The pre-dialysis Hct was 
0.24+0.02, the platelet count 183+31 G/l, the serum Na+: 139.3+4.6 tnM, K+: 5.4+0.4 mM, BUN: 
36.9+6.8 mM, creatinine: 929+112 pM. 
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3.2.2. Effect of rHu-EPO on the platelet function in ESRF children on HD 
8 patients with ESRF (4 boys and 4 girls, aged 6-17 years) who had been on bicarbonate 
HD for 31.8 months (10-68 months) and 8 age- and sex-matched controls were studied. Platelets 
from ESRF patients were investigated before and after 12 months of rHu-EPO therapy. rHu-EPO 
was administered sc.. In the first 12 weeks of the study, the dose of rHu-EPO was the same in all 
8 patients: weeks 1-4: 50 U/kg; weeks 5-8: 75 U/kg; weeks 9-12: 100 U/kg three times a week 
following HD. After 12 weeks the dose of rHu-EPO was individually modified to maintain a 
target Hct 0.35. The primary diagnosies in the ESRF group was 3 cases of chronic 
glomerulonephritis, 2 of hydronephrosis, 2 of renal agenesia with contralateral hypoplasia, and 1 
of polycystic kidney disease. The patients had a history of bleeding tendency (easy bruising and 
nose and gum bleeding). The ESRF patients were treated with bicarbonate HD (cuprophan 
dialyser, blood flow: 200 ml/min, duration: 210min.). Heparin was administered in an initial 
dose of 2000 IU, followed by an 800 IU/hr constant infusion. The pre-dialysis Hct was 
0.21±0.01 before and 0.36±0.01 after the 1-year rHu-EPO treatment. The serum concentrations 
were: Na+: 138.2±3.6 mM, K+: 5.3±0.3 mM, BUN: 35.8+7.1 mM, and creatinine: 917±121pM. 
There was no significant difference in the biochemical values following the 1-year rHu-EPO 
therapy. 
3.3. Plateletfunction, thromboxane and nitric oxide in hypertension of children and 
adolescents 
Examinations were performed on 14 patients with ESRF on chronic bicarbonate HD; 3 
times a week, 8 of them with hypertension (4 boys and 4 girls, aged 9-19 years) and 6 with 
normal blood pressure (3 boys and 3 girls, aged 8-18 years), on 12 patients with juvenile 
essential hypertension (JEHT) (6 boys 6 girls aged 12.7+4.1 years) and on 10 age- and sex-
matched controls. The patients with ESRF had an original nephrological diagnosies of 
obstructive uropathy (5), renal agenesia with hypoplastic kidney on the contralateral side (4), 
polycystic kidney disease (2), acute tubulointerstitial nephritis, with tubular necrosis (1), MPGN 
(1), or FSGS (1). In both hypertensive groups BP was investigated according to the WHO-ISH 
1999 Guideline (15) and Update on the 1987 Task Force Report on High Blood Pressure in 
Children and Adolescents. BP also was measured in all groups, with 24 hours ambulatory blood 
pressure monitoring (ABPM) (Meditech, APBM-04) (95). In the JEHT group, all secondary 
causes of hypertension were excluded; in this group the renal function and ultrasonographic 
findings were normal. The ESRF-associated hypertensive patients were treated with an ACE 
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inhibitor or calcium channel blockers, while the patients with JEHT were examined before the 
start of any treatment. 
3.4. Ethical issues 
The University Ethical Committee approved these studies. 
4. M E T H O D S 
Blood samples (9 ml) from a peripheral vein were collected in plastic tubes containing 1 
ml 3.8% trisodium citrate. Citrated blood was centrifiiged at 500 g for 10 min. at room 
temperature to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was obtained by 
centrifiigation of PRP at 4000g for 10 min.. The PRP platelet count was adjusted to 300±10 G/l. 
Plasma triglyceride, cholesterol, LDL-cholesterol, HDL-cholesterol, and VLDL-
cholesterol were determined by standard laboratory methods. 
4.1. Platelet aggregation 
Platelet aggregation was carried out with a laser-rheoaggregometer (Servobio, Meudon, 
France/48', using collagen stimulation (Hormon Chemie, Munich, Germany) at a final 
concentration of 2 p.g/ml. 
a: max .speed (diffusion) Aggregation unit (AU): max.speed (%/s) x max. intensity (%) 
b: max .speed (transmission) 
c: max.intensity (transmission) 
d: max.intensity (diffusion) 
Fig. 3. Platelet aggregation curves (transmission and diffusion) induced by collagen. 
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The aggregation of platelets from ESRF patients was induced with collagen in two 
concentrations: 1 or 3 pg/ml PRP. The apparatus was adjusted so that the PRP and PPP produced 
10% and 90% light transmittance, respectively. During aggregation, the changes in the 
transmittance of PRP were measured using a control of PRP obtained from the same patient. 
With this method, the disturbing effects of various plasma constituents (e.g. lipids) were avoided. 
Aggregating agent was added to PRP that had been stirred at 1000 rpm at 37 °C for 1 min. The 
speed and the intensity of the platelet aggregation curves obtained with transmitted light and 
diffused light simultaneously were estimated by computer analysis. The results of platelet 
aggregation were expressed in aggregation units. (Fig.3) 
4.2. Platelet adenosine triphosphate release 
ATP release from platelets during aggregation was studied with a Chronolog Lumi-
aggregometer. A parallel PRP sample (350 pi) was investigated by using luciferin as substrate 
and luciferase as enzyme (30pl) (Sigma, Poole, UK) (34) The amount of ATP released from 
platelets during aggregation stimulated by collagen was estimated from comparison of the peak 
of the curve obtained by the addition of 20 ng ATP (Sigma, Poole, UK) to a mixture of 350 pi 
0.9% NaCl and 30 pi luciferase-luciferin. The ATP release was expressed in ng/ml. The ATP 
sensitivity of this method is 0.5 ng/ml. 
4.3. Cyclic adenosine monophosphate concentration in platelets 
The concentration of cAMP in the platelets was measured following aggregation (36). 
Platelets were lysed and cAMP was released by cytolysis. During preparation, the platelet cAMP 
was protected from cAMP-dependent phosphodiesterase (PDE), with diluting buffer containing 
(in final concentrations) 0.5 tnM 3-isobutyl-l-methylxanthine (Sigma, Poole, UK), a specific 
PDE inhibitor, 4 tnM EDTA (Sigma, Poole, UK) and 50 mM TRIS-HC1 buffer (pH 7.5), and the 
mixture was centrifuged at 800g for 10 min. at 4 °C. The sediment was lysed in a hypotonic 
solution containing 4 mM EDTA, 8 mM theophylline and 20 mM TRIS-HC1 (pH 7.5). For more 
complete exposure of the platelets, boiling this mixture for 2 min. in a hot-water bath completed 
cytolysis (36). The protein free supernatant was obtained by centrifugation for 30 min. at 6000 g 
in a refrigerated centrifuge. cAMP was determined in 50 pi of the supernatant with a cAMP 
binding assay kit (Amersham TRK 432,Amersham, UK) The buffer used for binding assay was 
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the same as that used for cytolysis. Radioactive samples were measured in a Triton-toulene 
cocktail with a tritium programme with a Beckman LS 100C liquid scintillation counter. 
4.4. Platelet Thromboxane B2 release 
T X B 2 (the stabile metabolite of TxA2) levels were measured by radioimmunoassay (RIA) 
(40). This was carried out on aliquots of the supernatant after the measurement of platelet 
aggregation. The sensitivity of the method was 3 ng/ml. 
4.5. Platelet surface positive charge 
Platelet surface positive charge was measured by the method of Wojtczak and Nalecz (111) 
The binding of 8-aniline-l-naphthalene sulphate (ANS) to the platelet surface was measured 
with a Hitachi F2000 fluorimeter at 366 nm and 460 nm (excitation and emission wavelengths, 
respectively). 3 pi of 5 mM alcoholic ANS solution was added to 3 ml PRP and 3 ml PPP. 
Following each ANS challenge, the fluorescence intensity was measured and the value obtained 
before addition of ANS was subtracted from each post-ANS result and then related to the platelet 
number in the PRP and expressed in arbitrary units per platelets. 
4.6. Direct effect of rHu-EPO on platelet aggregation 
The direct effect of rHu-EPO on platelet aggregation was investigated in vivo and in vitro. In 
the in vivo study, platelet aggregation was determined prior to and 30 min. following 
intravenously administration of rHu-EPO. In the in vitro study, blood samples from uraemic 
patients were treated with rHu-EPO in vitro (10 U rHu-EPO in 10ml citrated blood at 37 °C for 
30 min.) and the platelet aggregation was measured prior and following incubation. The method 
was the same as described in session 4.1. 
4.7. Direct effects of red blood cell count on platelet aggregation 
The direct effects of the RBC count on platelet aggregation were investigated by preparing a 
low-Hct (0.23+0.02) and a high-Hct (0.38±0.02) sample in vitro using autologous RBCs. 
Following a 60-min. incubation at room temperature PRP was prepared from each samples and 
platelet aggregation was examined with a laser-rheoaggregometer as described in session 4.1. 
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4.8. Nitric oxide end-products in plasma (N0X) 
Nitrite and nitrate were simultaneously determined by an anion-exchange 
chromatographic HPLC method (1). The Pharmacia LKB HPLC system was used with a 
Variable Wavelength Detector (at 210 nm).(68) 
4.9. Statistical analysis 
All platelet aggregations, ATP, cAMP, TxB2, nitrite and nitrite measurements and platelet 
surface charge studies were carried out in duplicate. Statistical analysis was performed with the 
paired t-test and the rank correlation test with SigmaStat 1.0 statistical software. 
The results for the groups are given as means plus or minus standard errors (±SEM). 
5.RESULTS 
5.1. Platelet aggregation studies in nephrotic syndrome 
5.1.1. Platelet aggregation 
In vitro laser-rheoaggregometer studies revealed significantly higher diffusion and 
transmission results for platelets from nephrotic patients than for those from the controls 
(p<0.05). There was no significant difference between the groups in remission and in relapse. 
(Fig.4). The platelet aggregation results demonstrated a significantly higher aggregation for all 
the different histological subgroups than for the controls (p<0.01). The number of patients with 
MGN was too low for statistical analysis, although these patients displayed the highest platelet 
aggregability amongst the nephrotic children. 
The transmission values were significantly higher for the platelets from the patients with 
IgAN and SLE than for those from MCNS patients in early remission (p<0.05). Similarly, the 
diffusion values were higher in IgAN and SLE than in MCNS, although the differences were not 
significant (Table 5.). A significant positive correlation was observed between the diffusion and 
transmission in the nephrotic groups (r=0.85, p<0.05). 
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Table 5. Laser-rheoaggregometer studies with platelets from nephrotic patients 
Platelet Aggregation (AU) 
Diagnosis n Diffusion Transmission 
M C N S in remission 14 27185+3705* 11722+1006* 
in relapse 11 36913+3146* 12456+1503* 
FSGS 9 31409+5886* 12916+1012* 
M P G N 5 29325+4148 12572+2116 
SLE 7 31873+3194* 15657+2420* 
MGN 4 40574+3070 16419+954 
Controls 18 19898+3206 9769+918 
*p <0.05 
5.1.2. Platelet cAMP concentration 
The platelet cAMP concentration was significantly lower in the nephrotic patients than in 
controls (p<0.05). There was no significant difference between remission and relapse or between 
steroid-treated and non-treated patients in remission. (Table 6.) A significant negative correlation 
was detected between the platelet cAMP concentration and the diffusion results obtained with 
platelet aggregation (r= -0.64, p<0.05) 
Table 6. Platelet cAMP concentration, ATP release and TxB2 release in nephrotic syndrome 
n 
ATP release 
cAMP T X B 2 
(ng/ml) (pmol/109 platelets) (ng/ml) 
Nephrotic syndrome 
In relapse 33 100.9+28.4* 12.1+3.4* 13.2+1.9** 
In remission 22 92.2+18.9* 11.9+2.9* 13.0+2.1** 
Prednisolone positive 12 84.4+12.6* 12.2+2.7* 12.1+1.8** 
Prednisolone negative 11 97.5+11.0* 11.7+2.8* 14.2+2.2** 
Controls 18 34.2+10.4 25.5+2.1 6.9+1.8 
*p<0.05, **p<0.01 
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5.1.3. Platelet A TP release 
Platelets from nephrotic patients either in relapse or in remission released significantly 
more ATP than did those from the controls (p<0.01). A higher ATP release was observed in 
relapse than in the remission, and in remission group without prednisolone than in the group 
taking prednisolone, but the difference was not significant. There was a positive correlation 
between the ATP release and the diffusion (r=0.68, p<0.05), and the ATP release and 
transmission values (r=0.65, p<0.05) (Table 6.) 
5.1.4. Platelet TxB2 release 
TXB2 formation by platelets in response to collagen was significantly higher in the 
nephrotic patients than in the controls (p<0.01). No difference was observed between the results 
for the subgroups of nephrotic patients. (Table 6.) The correlation coefficients for the TxB2 
release and the diffusion and the transmission values were 0.68 and 0.67 respectively (p<0.05). 
A significant negative correlation was detected between the platelet cAMP concentration and 
TXB2 release (r=-0.63, p<0.05). 
gmolfl 
r 10 
r - m Platelet aggregation (diffusion) 
mmm Lipids 
AGGREGAT 10 N - CH OLESTER OL AG GR EGATI ON - TRIGLYCERI DES 
Fig. 4. 
Comparison of changes in platelet aggregation and plasma lipids (cholesterol and triglyceride) in 
nephrotic patients in relapse or in early remission. 
Cholesterol and TGs: NS rel. (nephrotic syndrome in relapse) - controls and NS rel. (nephrotic 
syndrome in remission): p<0,05. 
26 
5.1.5. Effect of lipids on platelet aggregation 
The platelet aggregability was similar in the nephrotic patients in relapse, or in early remission. 
The plasma cholesterol and triglyceride were significantly higher in relapse than in remission 
(p<0.05) or in the controls. (Fig.4) No correlation was observed between the platelet aggregation 
and serum cholesterol and triglyceride values. 
5.2. Comparison of platelet function in MCNS and FSGS 
5.2.1. Platelet aggregation 
The platelet aggregation was significantly higher in all the patient groups than in the age-
matched controls. FSGS and MCNS patients in relapse showed more elevated platelet 
aggregability than in MCNS patients in remission; the differences were not significant (p<0.05 
and p<0.01 respectively) (Table 7.). 
5.2.2. Platelet cAMP concentration 
The platelet cAMP concentration was significantly lower in all the investigated groups as 
compared to the controls (p<0.01). (Table 7.) A significant negative correlation was observed 
between the platelet aggregation and the platelet cAMP concentration (r=-0.62, p<0.05). 
Table 7. Platelet function in FSGS and in MCNS patients in relapse and in remission 
FSGS 
(A+P) 
MCNS 
relapse 
MCNS 
remission 
Control 
adult 
Control 
Paediatric 
Number of pts. 16 12 15 12 15 
Platelet aggregation 
(AU) 
287+381** 26954±3016** 25537±3165* 19898+3206 18648+3165 
TxB2 release 
(ng/ml) 
17.1+2.2** 12.1+3.4* 11.9+2.9* 7.1±1.6 6.9+1.8 
cAMP 
(pmol/109 platelets) 
14.1±2.9* 12.1±3.4* 11.7+2.7* 26.8+4.8 25.5+2.1 
A: adult. P: paediatric, ** p<0.01, * p<0.005 
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5.2.3. Platelet TxB2 release 
The platelet TxB2 release was higher in all the patients than in the controls (FSGS: 
p<0.01, MCNS in relapse and MCNS in remission: p<0.05) (Table 7.). A significant positive 
correlation was detected between platelet TxB2 release and the diffusion obtained with platelet 
aggregation (r=0.63, p<0.05). The correlation coefficient for the platelet TxB2 release and 
platelet cAMP concentration was significantly negative (r=-0.60, p<0.05). There was no 
significant difference, between the adult and paediatric controls in any of the investigated 
platelet function parameters. 
5.3 Effects of bicarbonate and acetate haemodialysis on the platelet aggregation 
5.3.1. Platelet aggregation 
The PRP platelet counts were slightly, but significantly reduced in the ESRF patients: 
350+5.1 G/l in normal subjects, 290+6.1 G/l in ESRF patients. Platelets from ESRF patients, 
either dialysed or treated conservatively, displayed a significantly lower aggregability than those 
from controls (pO.OOl). In response to 1 or 3 fig/ml collagen a significantly greater increase in 
platelet aggregation was observed following bicarbonate HD than following acetate HD 
(p<0.05). (Table 8.) We observed a significant difference in platelet aggregation between the 
conservatively treated and dialysed ESRF patients before and after acetate HD (p<0.05). 
Table 8. Platelet aggregation in ESRF 
Platelet aggregation induced by collagen 
n (AU) 
1 pg/ml 3 (ig/ml 
ESRF before acetate HD 6 905+457** 910+350** 
after acetate HD 954+450** 721+254** 
ESRF before bicarbonate HD 6 1390+454** 1363+542** 
after bicarbonate HD 1750+460** 2150+832** 
ESRF on conservative therapy 8 1520+330** 1704+380** 
Control 10 3150+580 4050+761 
** p< 0.001 
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There was no significant correlation between the serum PTH values and the platelet 
aggregability in the non-dialysed and dialysed ESRF patients 
5.3.2 Platelet cAMP concentration 
The platelet cAMP concentration was significantly higher in the ESRF patients (on 
conservative treatment, before bicarbonate and acetate HD) than in the controls. In the non-
aggregated platelets the cAMP concentration was decreased significantly following acetate and 
bicarbonate HD (p<0.05). The tendency was similar during bicarbonate HD in the aggregated 
platelets (aggregation was induced with either 1 or 3 mg/ml collagen, p<0.05). (Table 9.) 
A significant negative correlation was observed between the platelet aggregation value and the 
platelet cAMP concentration in all groups (r=-0.7, p<0.05). The intact PTH levels did not 
correlate with the platelet cAMP values. 
Table 9. Platelet cAMP concentration and TxB2 release in ESRF 
TxB2 cAMP pmol/109 platelets 
n ng/ml before lpg/ml 3 pg/ml 
Collagen 
ESRF before acetate HD 6 38.7+18.2** 100.6+28.4* 75.1+20.8* 90.7+20.6* 
after acetate HD 43.4+27.6** 44.5+7.41 56.7+18.7 86.5+20.7* 
ESRF before bicarbonate HD 6 56.5+28.9* 80.2+21.9* 88.9+22.1* 80.7+22.4* 
after bicarbonate HD 72.4+28.2* 25.2+16.1 42.7+18.9 43.1+20.4 
ESRF on conservative therapy 8 - 72.5+28.9* 101.9+37.3* 115.2+37.5* 
Control 10 112.1+29.1 35.5+6.5 38.8+5.1 54.0+8.8 
* p<0,05, ** p<0,01 
5.3.3. Platelet TxB2 release 
The TXB2 formation by the platelets in response to 3 (ig/ml collagen was measured in the 
dialysed (acetate FID and bicarbonate HD) and control groups. There was a significant difference 
between the values for the dialysed ESRF patients and the controls (p<0.01). The level of TxB2 
1*1 SZpr>T. 
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released from the aggregating platelets was increased more after bicarbonate HD than after 
acetate HD. The correlation coefficient for the platelet aggregability and the TxB2 level was 0.67 
(p<0.05). A negative correlation was observed between the platelet cAMP and TxB2 levels 
(r=0.60, p<0.05). There was no significant correlation between the serum PTH and the platelet 
5.4 Effect of rHu-EPO on platelet function in ESRF children on HD 
5.4.1. Bleeding time and platelet count 
Before rHu-EPO treatment, the pre-dialysis bleeding time was 9.4±0.6 min. which 
decreased to 5.7+0.6 min. following the 1-year rHu-EPO therapy (p<0.05). In the controls, it was 
4.6+0.8 min. There was no significant difference in the platelet count before (178+32 G/l) and 
after (187+26.5 G/l) 1 year of rHu-EPO treatment and in controls (241+12 G/l). The in vitro and 
in vivo studies did not reveal any direct effect of rHu-EPO on the platelet aggregability. The 
increased Hct in vitro did not influence the platelet aggregation (Table 10.). 
Table 10. Effect of rHu-EPO on the platelet aggregability in ESRF 
TXB2. 
Platelet aggregation 
(AU) 
In vivo study 
Before rHu-EPO 10140±2300 
After rHu-EPO 9464±3429 
In vitro study 
Before rHu-EPO 930811382 
After rHu-EPO 895011080 
Hct 0.2310.02 941511329 
Hct 0.3810.02 923911290 
Controls 2130511763 
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5.4.2. Platelet aggregation 
Platelets from the ESRF patients, either treated with rHu-EPO or non-treated, displayed a 
significantly lower aggregabilty in vitro, than those from the controls (p<0.001). One year of 
rHu-EPO therapy resulted in a significant increase in platelet aggregability (p<0.05). There was 
also an improvement following bicarbonate HD, either with or without rHu-EPO treatment 
(p<0.05, p<0.01 respectively) (Fig. 5A.). 
5.4.3. A TP release from the platelets 
A significantly lower ATP release was found from the ESRF platelets during aggregation 
(with or without rHu-EPO treatment) than from the controls (p<0.001). After 1 year of rHu-EPO 
therapy, the ATP release was significantly higher from the aggregated platelet than prior to rHu-
EPO treatment (p<0.05). Bicarbonate HD itself caused a significant increase in the ATP release 
with or without rHu-EPO therapy (p<0.01, Fig. 5B). A significant positive correlation was 
observed in both groups between platelet aggregation and ATP release (r = 0.78, p<0.05) 
A B 
4000 1 1 1 , :1-| :, 1 1 1 
Pre BHD Post BHD Control Pre BHD Post BHD Control 
Fig. 5. 
Changes in platelet aggregability (A) and ATP release from the platelet (B) prior to and following 1 year of rHu-
EPO therapy (±SEM) in the patients before and after bicarbonate HD. (V—V) BHD before rHu-EPO, ( • — • ) after 
1 year of rHu-EPO therapy. Patients with or without rHu-EPO therapy (either pre- or post-bicarbonate HD), p<0.05, 
patients before and after bicarbonate HD (with or without rHu-EPO), *p<0.05, **p<0.01, patients and controls 
***p<0,001. 
31 
5.4.4. Platelet cAMP concentration 
The platelet cAMP concentration was significantly higher before bicarbonate HD than in 
the controls, either with or without rHu-EPO therapy (p<0.05, p<0.01 respectively). 
Nevertheless, 1 year of rHu-EPO treatment resulted in a significant decrease in the platelet 
cAMP concentration (p<0.01). During bicarbonate HD, a significant decrease was observed in 
the values, regardless of the performance of rHu-EPO therapy (p<0.01, Fig.6B). There was 
significant negative correlation in both groups of patients between platelet aggregation and the 
platelet cAMP concentration.(r=-0.75, p<0.05) 
5.4.5. Platelet TxB2 release 
The TxB2 formation by the platelets in response to collagen was significantly lower in the ESRF 
patients (either with or without rHu-EPO) than in the controls (p<0.001). Following 1 year of 
rHu-EPO therapy, a significant increase was observed in the values (p<0.01). 
Fig. 6. 
TXB2 production (A) and cAMP concentration (B) in platelets during aggregation. 
(V — V) BHD before rHu-EPO, ( • — • ) after 1 year of rHu-EPO therapy. cAMP and TxB2, with or without rHu-
EPO (either pre- or post-bicarbonate HD) p<0.01; cAMP. patients (pre- dialysis with or without rHu-EPO) and 
controls, p<0.05 and p<0.01 respectively; patients (post- dialysis without rHu-EPO) and controls. p<0.05; no 
difference between patients (post-dialysis with rHu-EPO) and controls; patients before and after bicarbonate HD 
(with or without rHu-EPO), p<0.01; TXB2, patients with or without rHu-EPO, before and after bicarbonate HD and 
controls, p O . O l , pre- and post-bicarbonate HD p O . O l . 
**p<0.01, ***p<0.001, PRP: platelet-rich plasma 
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Bicarbonate HD (with or without rHu-EPO) resulted in an elevation in the TxB2 release 
(p<0.01, Fig. 6A). The correlation coefficient for the platelet aggregability and the TxB2 level 
was 0.68 (p<0.05). A negative correlation was observed between the platelet cAMP and TxB2 
levels (r= -0.62, p<0.05) 
5.4.6. Platelet surface positive charge 
The platelet positive surface charge (measured by ANS titration) was significantly lower 
in the ESRF patients than in the controls. rHu-EPO treatment did not influence the values 
significantly. Nevertheless bicarbonate HD resulted in a significant increase in the platelet 
surface positive charge (p<0.05), though it was still much lower than in the controls (Fig.7). A 
significant positive correlation was observed in both groups between the platelet aggregability 
and the surface positive charge (r= 0.76, p<0.05). 
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Fig. 7. 
Changes in platelet positive surface charge af ter bicarbonate H D (±SEM) (V — V ) B H D before rHu-
EPO, ( • — • ) af ter 1 year of rHu-EPO therapy. Pre- and post-bicarbonate H D , *p<0.05; patients (with or 
without rHu-EPO, before and af ter bicarbonate H D ) and controls ***p<0.01. 
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5.5 Role of platelet function, thromboxane and nitric oxide in hypertension of children and 
adolescents 
5.5.1. Blood pressure 
The systolic and diastolic blood pressure was significantly elevated in JEHT (p<0.001) 
and in ESRF-associated hypertension (ESRFH) before and after bicarbonate HD (p<0.001). The 
post-dialysis values were significantly higher than those prior to HD (p<0.05). There were no 
significant differences between the ESRF patients (before and after bicarbonate HD) and the 
controls. (Table 11.) 
5.5.2. Platelet aggregation 
The platelet aggregation was significantly higher in the JEHT and ESRFH groups 
following bicarbonate HD (p<0.01). A significantly reduced platelet aggregation as compared 
with the controls (p<0.01) was demonstrated in the ESRF group both before and after 
bicarbonate HD. There was a positive correlation between either the systolic or the diastolic 
blood pressure and the platelet aggregation (r=0.59 and r=0.56, respectively, p<0.05). 
Table 11. Systolic or the diastolic blood pressure and the platelet aggregation 
Diagnosis n Platelet aggregation 
(AU) 
Systolic BP 
(mm Hg) 
Diastolic BP 
(mm Hg) 
JEHT 33 33904+2869*** 174.1+14.9*** 106.3+10.4*** 
ESRFH before BHD 8 21599+3742** 157.1+13.6*** 99.2+8.9*** 
ESRFH after BHD 8 30629+4303*** 187.1+12.4*** 117.5+3.9*** 
ESRF before BHD 8 13846+1923* 114.4+9.1 80.2+6.2 
ESRF after BHD 8 13306+1923* 112.3+11.5 72.3+13.5 
Control 10 16893+1258 104.4+6.9 74.2+5.3 
JEHT: juvenile essential hypertension, ESRFH: ESRF-associated hypertension, BHD: bicarbonate haemodialysis. 
Statistical analysis - comparison with control values: p<0.05, **p<0.01, ***p<0.001 
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5.5.3. Platelet cAMP concentration 
The platelet cAMP concentration was significantly lower in the JEHT group (p<0.01) and 
in the ESRFH group after bicarbonate HD (p<0.001) as compared with the controls. In the ESRF 
group (before and after bicarbonate HD), the results did not reveal any significant differences 
from the control data. A negative correlation was found between the platelet aggregation and 
cAMP levels (r= -0.42, p<0.05) (Table 12.) 
5.3.4. Platelet TxB2 release 
TXB 2 release was significantly higher during platelet aggregation in the J E H T group 
(pCO.OOl) and in the E S R F H group (p<0.01 and p<0.001, respectively, before and after 
bicarbonate HD). The correlation was significantly positive between the platelet aggregation and 
TXB2 release data (r=0.47, p<0.05) No differences were observed in the platelet TxB2 results 
between the E S R F group and the controls. 
Table 12. Platelet cAMP concentration, TxB2 release and plasma NOx 
Diagnosis n PlateletTxB2 
(ng/ml PRP) 
cAMP 
(pinol/109 platelets) 
Plasma NOx 
(pM) 
JEHT 33 392+69*** 24.3+5.0*** 120+3.9** 
ESRFH before BHD 8 273+34** 29.1+4.0* 85.8+10.4 
ESRFH after BHD 8 388+29*** 15.4+7.3*** 59.7+6.8** 
ESRF before BHD 8 156.4+28.2 32.5+5.6 78.5+7.2 
ESRF after BHD 8 165.3+17.4 43.2+7.6 48.5+5.8** 
Control 10 178+16 39.1+9.6 89.0+21.0 
JEHT: juvenile essential hypertension, ESRFH: ESRF-associated hypertension, BHD: bicarbonate 
haemodialysis. Statistical analysis - comparison with control values: *p<0.05, **p<0.01, ***p<0.001 
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5.5.4. Nitric oxide end-products (N0X) in plasma 
The plasma N0X concentration was significantly higher in the JEHT group (p<0.01) and 
lower in the ESRF and ESRFH groups as compared with the controls (p<0.01). There was a 
weak negative correlation between the plasma NOx level and platelet aggregation (r=0.42, 
p<0.05). 
5.5.5. Plasma lipoproteins 
The plasma total cholesterol and triglyceride levels were significantly higher in each 
ESRF group as compared with the controls (before and after bicarbonate HD, p<0.05, ESRFH 
after bicarbonate HD, p<0.01). The LDL cholesterol level was significantly higher (p<0.001) and 
the HDL cholesterol level was lower (p<0.001) in the ESRF and ESRFH groups (before and 
after bicarbonate HD) as compared with the controls. All these lipoprotein values were normal in 
the JEHT group. There was no significant difference in plasma VLDL concentration between 
any patients group and the controls. No correlation was found between the plasma lipid values 
and the BP or the platelet aggregation. 
Table 13. Plasma lipoproteins 
Diagnosis n Cholesterol 
(mmol/1) 
Triglyceride 
(mmol/1) 
LDL 
cholesterol 
(%) 
HDL 
cholesterol 
(%) 
VLDL 
cholesterol 
(%) 
J E H T 12 4 .510.8 1.410.9 44.214.5 28 .215 .9 25.916.2 
E S R F H before H D 8 5.911.1* 2 .111.2* 64.415.5*** 15.210.8*** 19.213.9 
E S R F H after H D 8 5.610.5* 3.611.1** 62.716.2*** 15.410.5*** 21.213.4 
E S R F before H D 6 5 .810.7* 2.311.1* 58.315.3*** 15.610.4*** 24.112.2 
E S R F af ter H D 6 5.910.8* 2 .711.2* 53.616.1*** 15.810.5*** 25.316.4 
Controls 10 4 .510 .7 1.210.6 43.618.8** 28 .616.1 27 .718.1 
JEHT: juvenile essential hypertension, ESRFH: ESRF-associated hypertension, HD; haemodialysis. 
Statistical analysis - comparison with control values: *p<0.05, **p<0.01, ***p<0.001 
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6. DISCUSSION 
6.1. Nephrotic syndrome and platelet function 
A number of haemostatic parameters change in nephrotic syndrome. Increases have been 
found in coagulation factors (I, II, VIII, X and XII), due to the increased hepatic synthesis 
accompanying the increased syntheses of albumin and lipoproteins (1,65'74'79). The plasma 
fibrinogen level is elevated (1'65), as are the plasma concentrations of protein C and S. 
Antithrombin ID plays a major role in preventing the intravascular deposition of fibrin, but its 
level is decreased in nephrotic syndrome, because of the urinary loss. 
There is substantial evidence of an impaired platelet function during glomerular injury, 
primarily based on the detection of elevated plasma concentrations of platelet-derived 
substances, suggesting an enhanced platelet activity in children with nephrotic syndrome. 
Important differences may exist depending on the type of glomerular lesion. MGN is the most 
frequent glomerulonephritis in adults, and it is also the lesion in which thrombosis most common 
(74). Conversely, MCNS is the lesion least often complicated by thrombosis. Cameron ( U ) found 
no cases of renal venous thrombosis in MCNS, whereas Llach(64) reported an occurrence of 40% 
in MGN. In a survey of 155 nephrotic patients with renal venous thrombosis, 57% had MCN and 
only 6% had MCNS (65). Diffuse mesangiocapillary glomerulonephritis is also associated with 
thrombosis, but it is only one-third as frequent as MGN. Like patients with MCNS, those with 
FSGS have this complication only rarely. Of the secondary causes of nephrotic syndrome, 
thrombosis is often seen in SLE, diabetes mellitus and amyloidosis(74). 
Intraglomerular fibrin deposition and thrombosis may play important roles in the onset of 
glomerular sclerosis (9'50). The importance of glomerular fibrin formation is emphasised by the 
beneficial effects of anticoagulant or anti-platelet drugs, which in some studies markedly reduced 
the severity of the lesions and functional impairment in treated animals(81,82). 
In our laser-rheoaggregometer study, both transmission and diffusion methods revealed 
an increased in vitro aggregability in nephrotic patients. The transmission data showed that 
patients with IgA and SLE nephropathies have significantly higher platelet aggregability than 
those with MCNS in early remission, while no difference in platelet aggregation could be 
detected between MCNS patients in remission or in relapse. The highest level of platelet 
aggregation was observed in MGN patients, one of who had unilateral renal venous thrombosis. 
Abnormalities in the prostaglandin system may contribute to the platelet aggregation. Albumin is 
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involved in the transport of arachidonic acid. With hypoalbuminaemia, freer arachidonate is 
available for platelet cyclooxygenase, permitting an increased synthesis of thromboxanes, 
thereby fostering the aggregation of platelets (11). An increased platelet aggregation in response 
to arachidonic acid infusion has been demonstrated in platelets from nephrotic syndrome 
patients; this is normalised by the addition of albumin(1). 
Our study demonstrated an increased TxB2 release from the platelets of nephrotic patients 
either in relapse or in early remission, when no proteinuria was detected and the serum albumin 
level was undergoing normalisation. Our patients did not receive an albumin infusion. This 
means that in the early phase of remission the increased TxB2 production continues until the 
enhanced serum albumin and other regulatory mechanisms reduce it. The increased TxB2 level in 
remission was compatible with the increased aggregation results and the increased ATP release 
during aggregation. Ueda et al. (102) observed the hyperaggregation of platelets in response to 
ADP in nephrotic children, with no relationship to the serum albumin concentration. On the 
other hand, the cAMP concentration of the platelets from our patients with nephrotic syndrome 
was reduced. This may imply that, apart from the serum albumin level, intraplatelet mechanisms 
could play a role in the behaviour of platelets in nephrotic syndrome allowing Ca2+ release from 
the cytosol, which results in platelet activation. The effects of hyperlipidaemia and steroid 
therapy on the coagulation system and platelet function are not completely clear. The fluctuation 
in the antithrombin i n level in childhood nephrotic syndrome is determined by the response to 
steroids (28). In remission induced by prednisone, the platelet count and cholesterol, antithrombin 
III and protein C levels were still increased. This suggests that the steroid therapy could induce 
hyperlipidaemia and thrombosis. 
The change in platelet function of nephrotic patients is part of the changes in the 
haemostatic system. The extent of the hyperfiinction may vary with the type of glomerular 
lesion, and in some forms, e.g. MGN, thrombosis could develop, which is determined by the 
collective change in the haemostatic system. The serum albumin level is not the only factor 
influencing the platelet function, and the intraplatelet cAMP could play an important role in the 
extended hyperaggregation of platelets from nephrotic patients in remission. Low-dose oral 
steroid therapy and hyperlipidaemia per se do not increase platelet aggregation. On the other 
hand, nephrotic patients in early remission still have hyperaggregable platelets producing 
vasoconstrictor and proaggregatory factors, and more time is needed for normalisation. 
The question as to whether MCNS and FSGS, the two most common cause of nephrotic 
syndrome in childhood, are different entities or merely different manifestations of one disease 
remains unanswered. There are significant dissimilarities in the course of the disease and in the 
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effectiveness of the treatment of MCNS and FSGS. The increased platelet aggregability and 
TxB2 release suggesting that abnormalities may be involved in the pathogenesis of both MCNS 
and FSGS. The platelets TxB2 is significantly higher in FSGS than in MCNS, which may be 
have an impact in the progression of glomerular damage by an increased vasoconstriction and 
intraglomerular pressure. The intraplatelet cAMP is a regulator of platelet activity by inhibiting 
Ca2+ release from the cytosol (107). An increased production of cAMP results in a diminished 
adhesion and aggregation ability in the platelets. In the investigated FSGS and MCNS patients, 
the inhibitory effect of cAMP on the platelet activation is decreased by reduction of the platelet 
concentration. Interestingly, the patients with MCNS in remission still had platelet disorders. 
Koyama et al.(54) reported a vascular permeability factor, a postulated lymphokine, which 
induces nephrotic syndrome by weakening the GBM anionic charge. This factor impairs not only 
the GBM permeability, but also that of other cell membranes, as presumed by Levin et al.(60) and 
Boulton-Jones et al.(7). If this factor impairs the platelet function and still remains functional 
shortly after the proteinuria remission obtained with corticosteroid, this could explain these 
findings. 
6.2. Platelet function in ESRF patients 
The dysfunction of the platelets is one of the major contributing factors in the 
haemorrhagic tendency of patients with ESRF. The platelet aggregation is reduced in response to 
a variety of single agents (13'31). These abnormalities are partially and transiently corrected in 
some cases after HD and peritoneal dialysis (PD)(86'98). Therefore, it has been assumed that a low 
molecular weight inhibitor is present in these patients. Individual studies suggested that the 
inhibitor might be guanidinosuccinic acid (46'76), phenolic acid (85), urea (26) or a combination of 
these (89). di Minno et al.(19) found that uremic platelets have a defective aggregation, and they 
appear to release arachidonic acid from phospholipids abnormally after stimulation with some 
agents. However, the metabolism of exogenous arachidonic acid and the response to its 
metabolites are normal. There is also a modest reduction in the storage pool of adenine 
nucleotides. Dialysis resulted in partial correction of the abnormalities of aggregation and the 
arachidonic acid metabolism. However, it did not alter the storage pool defect. 
In this study, the platelets from dialysed or non-dialysed patients with ESRF showed a 
significantly higher cAMP, a lower TxB2 and a lower aggregability than, those of the platelets 
from the controls. These results are consistent with observations that in ESRF patients the 
platelet cAMP is increased (107). This elevation may contribute to the defective aggregation 
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response. The lower level of platelet TxB2 also observed by di Minno et al. (19), suggests a 
decreased release of arachidonic acid from platelet phospholipids in ESRF patients. Although the 
stimulation of platelets by aggregating agents is usually accompanied by a decrease in cAMP (90), 
in our patients (following 1 or 3 pg/ml collagen stimulation) the pre-dialysis (acetate HD) 
samples exhibited only slightly lower cAMP contents than before the addition of collagen. The 
platelet cAMP decreased more markedly after bicarbonate HD than after acetate HD, and greater 
increases in platelet aggregation and TxB2 formation were observed after bicarbonate HD than 
after acetate HD. One possible reason for the different results may be that acetate is a weak acid, 
and in protonated form it is lipid-soluble. It behaves as an uncoupling agent, prevents the 
phosphorylation of ADP to ATP, and possibly decreases the electrochemical potential on the 
internal mitochondria(59). In the platelets, experimental control is required. 
Lindsay at al. (62) demonstrated that platelets from ESRF patients aggregate normally in 
response to ADP as long as the serum creatinine level is less than 530 pM. The platelet 
aggregation was found to be impaired in patients with a more severe renal insufficiency. We 
have demonstrated that the platelet aggregability might be seriously impaired at a lower level of 
serum creatinine (average 480 pM) and the cAMP could be as high as in the dialysed patients 
with a higher level of serum creatinine. This might reflect the multifactorial origin of uraemic 
thrombocytopathy. In this respect, the possible role of concomitant hyperlipidaemia seen in 
dialysed ESRF patients should be taken into account (2'53'83). The picture is more complicated as 
regards the possible platelet activation induced by the dialysis membrane (6) or heparin (113). At 
the time of this study our patients had secondary hyperparathyroidism. It has been found that 
PTH inhibits the platelet aggregation induced by ADP, arachidonic acid and Ca2+ ionophore (90). 
It was hypothesised that PTH interferes with the platelet function by altering the platelet cAMP 
and/or Ca2+ level via the stimulation of adenylcyclase and the augmentation of intracellular 
cAMP. However a recent study did not find a correlation between the platelet function and the 
degree of hyperparathyroidism in ESRF patients. Moreover the platelet aggregation was more 
altered in the ESRF patients on conservative treatment than in the patients on chronic HD, in 
spite of the higher blood PTH level in the latter. In the patients of Docci et al.(21) treatment with 
l,25-(OH)2 Vitamin D3, which should normalise the elevated intraplatelet Ca2+ level, did not 
ameliorate the platelet dysfunction, thereby indicating that PTH can aggravate uremic 
thrombocytopathy, but is probably not the main factor which determines it. In our study, the 
ESRF patients on HD had much higher levels of PTH as compared to the ESRF patients on 
conservative treatment. The platelet cAMP and aggregability, particularly before and after 
bicarbonate HD, did not differ significantly from the results on the ESRF patients on 
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conservative treatment. These observations seem to confirm that there is no correlation between 
the serum PTH level and the degree of disturbances of the biochemistry and aggregation of 
uremic platelets. 
Many studies have investigated the effect of rHu-EPO on thrombotic complications in 
patients with ESRF who undergo HD or PD treatment with rHu-EPO; the results are 
controversial and only a slightly higher incidence of vascular access failure due to thrombosis 
has been reported (39'70'87). In our study, the bleeding time of the ESRF children was markedly 
shortened following 1 year of rHu-EPO treatment, as has been reported by other authors (39'70). 
The platelet aggregation increased in accordance with the results of Fabris et al. (33). Taylor et al 
(100) reported an improvement in spontaneous platelet aggregation in ESRF patients on HD and 
rHu-EPO therapy. Although the bleeding time normalised in our patients and the platelet 
aggregation increased, it was still lower than in the controls. Therefore we could not exclude the 
beneficial effect of the increased Hct on the bleeding time. Nevertheless, our in vitro study 
indicated that the increased Hct did not increase the platelet aggregation. Accordingly, an 
increased RBC count does not influence the platelet aggregability. rHu-EPO itself did not have a 
direct effect on aggregation, in either the in vitro, or the in vivo experiment. Thrombotic events 
did not develop in our patients during the treatment time. Horina et al. (45) demonstrated an 
increased platelet count during rHu-EPO therapy, which was not confirmed in our study. 
However, we observed a number of changes in the platelet biochemistry during rHu-EPO 
treatment. There were significant increases in platelet ATP release and TxB2 production, which 
further increased during bicarbonate HD, as did the platelet aggregability. Van Geet et al. (103) 
and Fabris et al. (33) also observed increased TxB2 production during rHu-EPO therapy. At the 
same time the platelet cAMP concentration decreased significantly. Vasiri et al. (104) recently 
reported that the observed improvement of the platelet function with rHu-EPO therapy is due to a 
correction of the defective Ca2+ signalling in the platelets. 
The presence of the platelet surface positive charge was demonstrated by ANS titration. 
These results revealed a significant correlation with the platelet aggregability. In most biological 
membranes, the resultant charge is negative (43). The surface of the platelets (67) and other blood 
cells (32) is negatively charged, largely due to the presence of sialic acid residues in the GPs and 
glycolipids of the cell membranes. Factors decreasing the proportion of surface positive charge 
on the platelets make the membrane more negative and probably reduce the adherence of cells to 
the endothelium. The nature of these substances is not yet known. Cationic surfactants decrease, 
whereas anionic surfactants increase the negative surface charge. The beneficial effect of 
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bicarbonate HD suggests the role of uraemic toxins and pH, which change during dialysis 
sessions, but not on rHu-EPO therapy. 
6.3. Hypertension in children and adolescents 
An important interaction occurs between hyperlipidaemia and hypertension. 
Hypertension exaggerates a hyperlipidaemic injury, and hyperlipidaemia alters the systemic and 
glomerulo-vascular production of vasoactive substances, which maintain the basal vascular tone 
(5i,66) H a y a k a w a a n ( j Raij (42) revealed that lipid oxidation products might reduce the NO 
bioactivity without affecting the endothelial nitric oxide synthase (NOS) activity. A decreased 
NO bioavailability does not necessarily result in systemic hypertension, but it may enhance the 
sensitivity of the hypertensiogenic effect of dietary salt. In our patients with JEHT, the total 
cholesterol and LDL cholesterol levels were normal, which is very uncommon in adult patients 
with essential hypertension. The role of dyslipidaemia in JEHT cannot be supported. Other risk 
factors, such as smoking, diabetes and alcohol consumption, can also be excluded in these 
patients with JEHT. The absence of dyslipidaemia in JEHT and the presence of ESRF with or 
without hypertension may exclude its pathogenetic role in JEHT, and it seems to be a 
consequence of ESRF rather than the cause of hypertension. Nevertheless, hyperlipidaemia and 
dyslipidaemia may increase the progression of vascular damage in ESRF-associated 
hypertension. 
In vitro platelet aggregability and TxB2 release were significantly higher in the JEHT and 
ESRFH groups. Although ESRF itself is associated with low platelet aggregability, this becomes 
increased in hypertension. The platelet aggregation was independent of the plasma lipid 
concentration, but there was a significant positive correlation between the platelet aggregation 
and T X B 2 release. The lower level of platelet cAMP resulted in a reduced control in platelet 
activation in both hypertensive groups. In these patients, the significantly higher TxB2 release 
may contribute to a generalised vasoconstriction and a further increase in platelet aggregation. 
Our patients with JEHT and ESRFH presented a significant positive correlation between the 
platelet aggregation and the blood pressure. In the study by Riondino et al. (92), significant 
correlations were observed between all platelet function parameters and blood pressure values. 
An increased platelet aggregation in JEHT may therefore play a role in the progression of 
hypertension before the development of atherosclerosis. Hypertension and platelet 
hyperaggregability might have a common aetiological factor. As demonstrated by Riondino et al. 
(92) in a population of older hypertensive patients with no other risk factor or atherogenic disease, 
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normalisation of the blood pressure resulted in a significant reduction in platelet hyperactivity. In 
ESRFH, the platelets are over activated, probably by the same factors as those responsible for the 
hypertension. The increased platelet aggregation with hyperlipidaemia and dyslipidaemia (a high 
level of LDL cholesterol and a low level of HDL cholesterol) may increase the progression of 
atherosclerosis and hypertension in ESRFH. 
AT II may stimulate endothelial NOS activity and NO release, which could further inhibit the 
ACE activity and down-regulate the AT-1 receptor via a negative feedback (108). An increase in 
NO generation would be balanced by an activation of the RAS and AT I synthesis, which might 
compete with NO for the active centre of ACE. A lack of NO, results in an increased action of 
AT II with severe pathophysiological consequences. Our patients with ESRFH displayed 
significantly decreased level of plasma NOx by the end of HD in parallel with a markedly 
increased blood pressure. This may correspond to the ACE and AT-1 receptor modelling role of 
NO. In JEHT patients, the observed elevation in plasma NOx level might be a result of AT II 
stimulation or The explanation of the missing vasodilatator effect of NO could be an increased 
degradation, probably caused by superoxide anion released from the dysfunctional vascular 
endothelium (105). Endothelin-1 produced locally could strengthen the effects of other 
vasoconstrictors. Besides its vasoactive properties, NO inhibits the platelet aggregation in vitro 
and platelet adhesion to cultured endothelial cells (38'66). The anti-platelet properties of NO in 
vivo may not be so efficient in the presence in the presence of NO inhibitors (e.g. renal failure, 
pre-eclampsia, JEHT), a mechanism that may provide an explanation for increased risk of 
vascular thrombotic events in this cases, including hypertensive children and adolescents(38). 
7. CONCLUSIONS 
7.1. Our study did not reveal any significant difference in the results of platelet aggregation, 
ATP release, TxB2 release, or platelet cAMP concentration between steroid-treated and non-
treated patients. The plasma cholesterol and triglyceride levels were significantly higher in 
relapse than in remission; nevertheless, no differences in platelet function were seen between 
these groups. In conclusion oral prednisone therapy on alternate days and the high cholesterol 
and triglyceride level in the plasma cannot be responsible for the hyperaggregation of platelets in 
nephrotic children. 
7.2. The increased platelet aggregability and TxB2 release suggesting that abnormalities may 
be involved in the pathogenesis of both MCNS and FSGS. The platelets TxB2 is significantly 
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higher in FSGS than in MCNS, which may be have an impact in the progression of glomerular 
damage by an increased vasoconstriction and intraglomerular pressure. 
7.3. Our results demonstrate that platelets from dialysed or non-dialysed ESRF patients 
display a significantly higher cAMP, a lower TxB2 and a lower aggregability, than those of the 
controls. 
7.4. Role of PTH, in spite of its significant increase, seems to be less important. Our 
observations seem to confirm that there is no correlation between the serum PTH level and the 
degree of disturbances of the biochemistry and aggregation of platelets of ESRF patients. 
7.5. Platelet cAMP level decreased more markedly during bicarbonate HD, than during 
acetate HD, and greater increases in platelet aggregation and TxB2 formation were observed 
following bicarbonate HD. 
7.6. Normalisation of the bleeding time following 1 year of rHu-EPO therapy was not 
associated with the normalisation of the platelet aggregability and biochemistry, we can not 
exclude the role of the increased Hct in the shortening of the bleeding time. However, the 
increased RBC count did not improve the platelet aggregation. Although rHu-EPO itself did not 
improve the platelet aggregation directly during 1 year of rHu-EPO therapy, a number of platelet 
functional changes were observed, including increased aggregability, and ATP and TxB2, release 
and a decrease in cAMP concentration. These contribute to the improvement of the bleeding 
time. Therefore we consider that rHu-EPO therapy can improve the platelet function through 
biochemical changes and has a combined effect on the haemostasis of ESRF patients. 
7.7. Increased platelet aggregation and TxB2 are characteristic feature of juvenile essential 
hypertension and ESRF associated hypertension, contributing the blood pressure elevation, while 
hyperlipidaemia is more common in ESRF, regardless blood pressure and does not have a role in 
the pathogenesis of JEHT at an early stage. In addition JEHT patients exhibits a compensatory 
increases in plasma NO level. The anti-platelet properties of NO may not be so efficient in the 
presence of NO inhibitors, a mechanism that may provide an explanation for increased platelet 
aggregability in these cases. 
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